Literature DB >> 3220770

Squamous cell carcinoma of the head and neck treated with radiotherapy: does planned neck dissection reduce the change for successful surgical management of subsequent local recurrence?

W M Mendenhall1, J T Parsons, R J Amdur, N J Cassisi, R R Million.   

Abstract

For patients with squamous cell carcinoma of the head and neck whose primary lesion is managed with radiotherapy, radiotherapy alone or in combination with neck dissection may be used to treat clinically positive neck nodes. Although these two treatment options produce similar control rates for small mobile nodes, it is our impression that radiotherapy plus neck dissection is the preferred treatment for more advanced neck disease. The question that arises is whether the addition of a neck dissection after radiotherapy will decrease the likelihood of successful surgical management of a subsequent recurrence at the primary site. In an effort to answer this question, the records of 227 patients with squamous cell carcinoma of the head and neck were reviewed. All patients had clinically positive neck nodes and were treated with radiotherapy alone to the primary lesion. There was no apparent difference in the rate of disease control at the primary site or in the ability to manage patients successfully who developed a local recurrence when comparing patients initially treated with radiotherapy alone to those managed by radiotherapy and neck dissection. We conclude that postradiotherapy neck dissection does not decrease the likelihood of successfully managing a recurrence at the primary site.

Entities:  

Mesh:

Year:  1988        PMID: 3220770     DOI: 10.1002/hed.2890100503

Source DB:  PubMed          Journal:  Head Neck Surg        ISSN: 0148-6403


  1 in total

1.  Neck dissection after chemoradiotherapy for oropharyngeal and hypopharyngeal cancer: the correlation between cervical lymph node metastasis and prognosis.

Authors:  Nobuhiro Hanai; Daisuke Kawakita; Taijiro Ozawa; Hitoshi Hirakawa; Takeshi Kodaira; Yasuhisa Hasegawa
Journal:  Int J Clin Oncol       Date:  2013-01-23       Impact factor: 3.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.